A federal class-action suit contends Rodan + Fields hid prostaglandin risks from customers who used its Lash Boost product, which this has implications for the entire lash-enhancement market. Plaintiffs say they wouldn’t have purchased the product–and endured the alleged adverse effects– if they had been told about the risks. Find out what that means for marketers of cosmetic lash enhancers that still use prostaglandin analogs (vs. peptides or botanical extracts). The suit will likely draw fresh attention to the use of prostaglandin analogs in eyelash enhancers; this issue has sparked FDA enforcement action in the past. Will it do so now?